Animal models reveal distinct mechanisms behind fatty liver disease in lean people, with GLP-1 drugs showing therapeutic promise
Lean MASLD (fatty liver disease in normal-weight people) has distinct mechanisms from obesity-related MASLD, with animal models showing GLP-1 analogues like exendin-4 and liraglutide as promising therapeutic candidates.
Quick Facts
What This Study Found
Lean MASLD is mechanistically distinct from obesity-related MASLD, driven by bile acid dysregulation, leptin signaling abnormalities, and oxidative stress. Animal models testing GLP-1 analogues (exendin-4, liraglutide), kinsenoside, silibinin, and bile acid modulators show therapeutic promise for this patient population.
Key Numbers
Literature search: PubMed and Scopus, January 2000 to June 2025. Models reviewed include MCD diet, choline-deficient diet, cholesterol/bile acid diets, Pemt-/- and cGas-/- genetic models. Candidate therapies include exendin-4 (GLP-1 analog).
How They Did This
Systematic literature review of PubMed and Scopus (January 2000-June 2025) covering dietary, genetic, and bile acid-focused animal models of lean MASLD.
Why This Research Matters
Lean MASLD is often underdiagnosed because patients lack the obesity typically associated with fatty liver disease. Understanding its unique mechanisms through appropriate animal models is essential for developing targeted therapies, including peptide-based treatments, for this overlooked patient population.
The Bigger Picture
This review highlights that not all fatty liver disease is the same—lean patients have distinct biological drivers that require tailored treatments. GLP-1 peptide analogues, already proven in obesity and diabetes, may have a specific role in lean MASLD through mechanisms beyond weight loss, potentially including direct liver-protective effects.
What This Study Doesn't Tell Us
Animal models cannot fully replicate human lean MASLD. Most therapeutic candidates are at preclinical stages. The review acknowledges that no single animal model captures all features of human lean MASLD.
Questions This Raises
- ?Can GLP-1 analogues treat lean MASLD through mechanisms independent of weight loss?
- ?Which animal model best predicts therapeutic response in human lean MASLD?
- ?Should lean MASLD patients be specifically included in clinical trials for peptide-based liver therapeutics?
Trust & Context
- Key Stat:
- Lean ≠ obesity MASLD Distinct mechanisms (bile acid dysregulation, leptin signaling, oxidative stress) drive liver disease in lean patients, requiring tailored therapies
- Evidence Grade:
- Comprehensive literature review of preclinical models. Provides strong mechanistic insights but all therapeutic evidence is from animal studies without clinical validation in lean MASLD patients.
- Study Age:
- Published in 2025; covers literature through June 2025, representing the most current preclinical evidence.
- Original Title:
- Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery.
- Published In:
- Expert opinion on drug discovery, 20(12), 1683-1700 (2025)
- Authors:
- Papadakos, Stavros P, Georgiadou, Chara, Kassi, Eva, Velliou, Rallia-Iliana, Chatzigeorgiou, Antonios
- Database ID:
- RPEP-12948
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
What is lean MASLD?
Lean MASLD (metabolic dysfunction-associated steatotic liver disease) is fatty liver disease that occurs in people with a normal BMI. Unlike obesity-related fatty liver, it is driven by different mechanisms including bile acid problems, altered leptin signaling, and oxidative stress, and can still progress to serious liver damage.
Could GLP-1 drugs help lean people with fatty liver disease?
Animal studies suggest GLP-1 analogues like exendin-4 and liraglutide show promise for lean MASLD, potentially through direct liver-protective effects rather than weight loss. However, clinical trials specifically in lean MASLD patients are needed to confirm these findings.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12948APA
Papadakos, Stavros P; Georgiadou, Chara; Kassi, Eva; Velliou, Rallia-Iliana; Chatzigeorgiou, Antonios. (2025). Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery.. Expert opinion on drug discovery, 20(12), 1683-1700. https://doi.org/10.1080/17460441.2025.2579124
MLA
Papadakos, Stavros P, et al. "Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery.." Expert opinion on drug discovery, 2025. https://doi.org/10.1080/17460441.2025.2579124
RethinkPeptides
RethinkPeptides Research Database. "Animal models of lean metabolic dysfunction-associated steat..." RPEP-12948. Retrieved from https://rethinkpeptides.com/research/papadakos-2025-animal-models-of-lean
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.